Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Smartphone Level Test Measures Disability in Several Neurological Domains for Patients With Multiple Sclerosis.

Boukhvalova AK, Fan O, Weideman AM, Harris T, Kowalczyk E, Pham L, Kosa P, Bielekova B.

Front Neurol. 2019 May 28;10:358. doi: 10.3389/fneur.2019.00358. eCollection 2019.

2.

Pediatric CNS-isolated hemophagocytic lymphohistiocytosis.

Benson LA, Li H, Henderson LA, Solomon IH, Soldatos A, Murphy J, Bielekova B, Kennedy AL, Rivkin MJ, Davies KJ, Hsu AP, Holland SM, Gahl WA, Sundel RP, Lehmann LE, Lee MA, Alexandrescu S, Degar BA, Duncan CN, Gorman MP.

Neurol Neuroimmunol Neuroinflamm. 2019 Apr 8;6(3):e560. doi: 10.1212/NXI.0000000000000560. eCollection 2019 May.

3.

Body Mass Index in Multiple Sclerosis modulates ceramide-induced DNA methylation and disease course.

Castro K, Ntranos A, Amatruda M, Petracca M, Kosa P, Chen EY, Morstein J, Trauner D, Watson CT, Kiebish MA, Bielekova B, Inglese M, Katz Sand I, Casaccia P.

EBioMedicine. 2019 May;43:392-410. doi: 10.1016/j.ebiom.2019.03.087. Epub 2019 Apr 10.

4.

Central nervous system-restricted familial hemophagocytic lymphohistiocytosis responds to hematopoietic cell transplantation.

Li H, Benson LA, Henderson LA, Solomon IH, Kennedy AL, Soldatos A, Bielekova B, Murphy J, Davies KJ, Lehmann LE, Lee MA, Alexandrescu S, Degar BA, Gorman MP, Duncan CN.

Blood Adv. 2019 Feb 26;3(4):503-507. doi: 10.1182/bloodadvances.2018027417. No abstract available.

5.

Cerebrospinal fluid biomarkers link toxic astrogliosis and microglial activation to multiple sclerosis severity.

Masvekar R, Wu T, Kosa P, Barbour C, Fossati V, Bielekova B.

Mult Scler Relat Disord. 2019 Feb;28:34-43. doi: 10.1016/j.msard.2018.11.032. Epub 2018 Dec 5.

PMID:
30553167
6.

Author Correction: Neuroimmune disorders of the central nervous system in children in the molecular era.

Wells E, Hacohen Y, Waldman A, Tillema JM, Soldatos A, Ances B, Benseler S, Bielekova B, Dale RC, Dalmau J, Gaillard W, Gorman M, Greenberg B, Hyslop A, Pardo CA, Tasker RC, Yeh EA, Bar-Or A, Pittock S, Vanderver A, Banwell B; attendees of the International Neuroimmune Meeting.

Nat Rev Neurol. 2018 Dec;14(12):749. doi: 10.1038/s41582-018-0077-9.

PMID:
30442924
7.

NeurEx: digitalized neurological examination offers a novel high-resolution disability scale.

Kosa P, Barbour C, Wichman A, Sandford M, Greenwood M, Bielekova B.

Ann Clin Transl Neurol. 2018 Sep 24;5(10):1241-1249. doi: 10.1002/acn3.640. eCollection 2018 Oct.

8.

Identifying and Quantifying Neurological Disability via Smartphone.

Boukhvalova AK, Kowalczyk E, Harris T, Kosa P, Wichman A, Sandford MA, Memon A, Bielekova B.

Front Neurol. 2018 Sep 4;9:740. doi: 10.3389/fneur.2018.00740. eCollection 2018.

9.

Intrathecal B Cells in MS Have Significantly Greater Lymphangiogenic Potential Compared to B Cells Derived From Non-MS Subjects.

Stein J, Xu Q, Jackson KC, Romm E, Wuest SC, Kosa P, Wu T, Bielekova B.

Front Neurol. 2018 Jul 20;9:554. doi: 10.3389/fneur.2018.00554. eCollection 2018.

10.

Neuroimmune disorders of the central nervous system in children in the molecular era.

Wells E, Hacohen Y, Waldman A, Tillema JM, Soldatos A, Ances B, Benseler S, Bielekova B, Dale RC, Dalmau J, Gaillard W, Gorman M, Greenberg B, Hyslop A, Pardo CA, Tasker RC, Yeh EA, Bar-Or A, Pittock S, Vanderver A, Banwell B; attendees of the International Neuroimmune Meeting.

Nat Rev Neurol. 2018 Jul;14(7):433-445. doi: 10.1038/s41582-018-0024-9. Review. Erratum in: Nat Rev Neurol. 2018 Dec;14(12):749.

PMID:
29925924
11.

CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.

Romme Christensen J, Komori M, von Essen MR, Ratzer R, Börnsen L, Bielekova B, Sellebjerg F.

Mult Scler. 2019 Jun;25(7):937-946. doi: 10.1177/1352458518774880. Epub 2018 May 18.

PMID:
29775134
12.

Daclizumab Therapy for Multiple Sclerosis.

Bielekova B.

Cold Spring Harb Perspect Med. 2019 May 1;9(5). pii: a034470. doi: 10.1101/cshperspect.a034470. Review.

13.

New Multiple Sclerosis Disease Severity Scale Predicts Future Accumulation of Disability.

Weideman AM, Barbour C, Tapia-Maltos MA, Tran T, Jackson K, Kosa P, Komori M, Wichman A, Johnson K, Greenwood M, Bielekova B.

Front Neurol. 2017 Nov 10;8:598. doi: 10.3389/fneur.2017.00598. eCollection 2017.

14.

Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments.

Weideman AM, Tapia-Maltos MA, Johnson K, Greenwood M, Bielekova B.

Front Neurol. 2017 Nov 10;8:577. doi: 10.3389/fneur.2017.00577. eCollection 2017.

15.

Promise, Progress, and Pitfalls in the Search for Central Nervous System Biomarkers in Neuroimmunological Diseases: A Role for Cerebrospinal Fluid Immunophenotyping.

Bielekova B, Pranzatelli MR.

Semin Pediatr Neurol. 2017 Aug;24(3):229-239. doi: 10.1016/j.spen.2017.08.001. Epub 2017 Aug 12. Review.

16.

Molecular-based diagnosis of multiple sclerosis and its progressive stage.

Barbour C, Kosa P, Komori M, Tanigawa M, Masvekar R, Wu T, Johnson K, Douvaras P, Fossati V, Herbst R, Wang Y, Tan K, Greenwood M, Bielekova B.

Ann Neurol. 2017 Nov;82(5):795-812. doi: 10.1002/ana.25083.

17.

Pharmacodynamic effects of daclizumab in the intrathecal compartment.

Komori M, Kosa P, Stein J, Zhao V, Blake A, Cherup J, Sheridan J, Wu T, Bielekova B.

Ann Clin Transl Neurol. 2017 May 29;4(7):478-490. doi: 10.1002/acn3.427. eCollection 2017 Jul.

18.

Finger and foot tapping as alternative outcomes of upper and lower extremity function in multiple sclerosis.

Tanigawa M, Stein J, Park J, Kosa P, Cortese I, Bielekova B.

Mult Scler J Exp Transl Clin. 2017 Jan 1;3(1):2055217316688930. doi: 10.1177/2055217316688930. eCollection 2017 Jan-Mar.

19.

The effects of interleukin-2 on immune response regulation.

Waters RS, Perry JSA, Han S, Bielekova B, Gedeon T.

Math Med Biol. 2018 Mar 14;35(1):79-119. doi: 10.1093/imammb/dqw021.

20.

Cerebrospinal Fluid Cytokines Correlate With Aseptic Meningitis and Blood-Brain Barrier Function in Neonatal-Onset Multisystem Inflammatory Disease: Central Nervous System Biomarkers in Neonatal-Onset Multisystem Inflammatory Disease Correlate With Central Nervous System Inflammation.

Rodriguez-Smith J, Lin YC, Tsai WL, Kim H, Montealegre-Sanchez G, Chapelle D, Huang Y, Sibley CH, Gadina M, Wesley R, Bielekova B, Goldbach-Mansky R.

Arthritis Rheumatol. 2017 Jun;69(6):1325-1336. doi: 10.1002/art.40055. Epub 2017 May 10.

21.

Spinal Arachnoiditis as a Complication of Cryptococcal Meningoencephalitis in Non-HIV Previously Healthy Adults.

Panackal AA, Komori M, Kosa P, Khan O, Hammoud DA, Rosen LB, Browne SK, Lin YC, Romm E, Ramaprasad C, Fries BC, Bennett JE, Bielekova B, Williamson PR.

Clin Infect Dis. 2017 Feb 1;64(3):275-283. doi: 10.1093/cid/ciw739. Epub 2016 Nov 10.

22.

Perspective: Who dares, wins.

Bielekova B.

Nature. 2016 Nov 30;540(7631):S10. doi: 10.1038/540S10a. No abstract available.

23.

Sustained reduction of MS disability: New player in comparing disease-modifying treatments.

Bielekova B, Tintore M.

Neurology. 2016 Nov 8;87(19):1966-1967. Epub 2016 Oct 12. No abstract available.

PMID:
27733564
24.

Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment.

Kosa P, Ghazali D, Tanigawa M, Barbour C, Cortese I, Kelley W, Snyder B, Ohayon J, Fenton K, Lehky T, Wu T, Greenwood M, Nair G, Bielekova B.

Front Neurol. 2016 Aug 15;7:131. doi: 10.3389/fneur.2016.00131. eCollection 2016.

25.

Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis.

Komori M, Lin YC, Cortese I, Blake A, Ohayon J, Cherup J, Maric D, Kosa P, Wu T, Bielekova B.

Ann Clin Transl Neurol. 2016 Feb 1;3(3):166-79. doi: 10.1002/acn3.293. eCollection 2016 Mar.

26.

Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination.

Lin YC, Winokur P, Blake A, Wu T, Manischewitz J, King LR, Romm E, Golding H, Bielekova B.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(1):e196. doi: 10.1212/NXI.0000000000000196. eCollection 2016 Feb.

27.

Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.

Cortese I, Ohayon J, Fenton K, Lee CC, Raffeld M, Cowen EW, DiGiovanna JJ, Bielekova B.

Neurology. 2016 Mar 1;86(9):847-55. doi: 10.1212/WNL.0000000000002417. Epub 2016 Feb 3.

28.

Pioglitazone regulates myelin phagocytosis and multiple sclerosis monocytes.

Natrajan MS, Komori M, Kosa P, Johnson KR, Wu T, Franklin RJ, Bielekova B.

Ann Clin Transl Neurol. 2015 Oct 27;2(12):1071-84. doi: 10.1002/acn3.260. eCollection 2015 Dec.

29.

Novel composite MRI scale correlates highly with disability in multiple sclerosis patients.

Kosa P, Komori M, Waters R, Wu T, Cortese I, Ohayon J, Fenton K, Cherup J, Gedeon T, Bielekova B.

Mult Scler Relat Disord. 2015 Nov;4(6):526-35. doi: 10.1016/j.msard.2015.08.009. Epub 2015 Aug 28.

30.

Retinoid X receptor activation reverses age-related deficiencies in myelin debris phagocytosis and remyelination.

Natrajan MS, de la Fuente AG, Crawford AH, Linehan E, Nuñez V, Johnson KR, Wu T, Fitzgerald DC, Ricote M, Bielekova B, Franklin RJ.

Brain. 2015 Dec;138(Pt 12):3581-97. doi: 10.1093/brain/awv289. Epub 2015 Oct 12.

31.

Incomplete Susac syndrome exacerbated after natalizumab.

Zhovtis Ryerson L, Kister I, Snuderl M, Magro C, Bielekova B.

Neurol Neuroimmunol Neuroinflamm. 2015 Sep 24;2(5):e151. doi: 10.1212/NXI.0000000000000151. eCollection 2015 Oct. No abstract available.

32.

Paradoxical Immune Responses in Non-HIV Cryptococcal Meningitis.

Panackal AA, Wuest SC, Lin YC, Wu T, Zhang N, Kosa P, Komori M, Blake A, Browne SK, Rosen LB, Hagen F, Meis J, Levitz SM, Quezado M, Hammoud D, Bennett JE, Bielekova B, Williamson PR.

PLoS Pathog. 2015 May 28;11(5):e1004884. doi: 10.1371/journal.ppat.1004884. eCollection 2015 May.

33.

Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis.

Lin YC, Winokur P, Blake A, Wu T, Romm E, Bielekova B.

Ann Clin Transl Neurol. 2015 May;2(5):445-55. doi: 10.1002/acn3.181. Epub 2015 Apr 7.

34.

Will CSF biomarkers guide future therapeutic decisions in multiple sclerosis?

Bielekova B, McDermott MP.

Neurology. 2015 Apr 21;84(16):1620-1. doi: 10.1212/WNL.0000000000001506. Epub 2015 Mar 25. No abstract available.

PMID:
25809305
35.

Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis.

Komori M, Blake A, Greenwood M, Lin YC, Kosa P, Ghazali D, Winokur P, Natrajan M, Wuest SC, Romm E, Panackal AA, Williamson PR, Wu T, Bielekova B.

Ann Neurol. 2015 Jul;78(1):3-20. doi: 10.1002/ana.24408. Epub 2015 Apr 16.

36.

CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.

Elkins J, Sheridan J, Amaravadi L, Riester K, Selmaj K, Bielekova B, Parr E, Giovannoni G.

Neurol Neuroimmunol Neuroinflamm. 2015 Jan 22;2(2):e65. doi: 10.1212/NXI.0000000000000065. eCollection 2015 Apr.

37.

A complex role of herpes viruses in the disease process of multiple sclerosis.

Wuest SC, Mexhitaj I, Chai NR, Romm E, Scheffel J, Xu B, Lane K, Wu T, Bielekova B.

PLoS One. 2014 Aug 22;9(8):e105434. doi: 10.1371/journal.pone.0105434. eCollection 2014.

38.

How implementation of systems biology into clinical trials accelerates understanding of diseases.

Bielekova B, Vodovotz Y, An G, Hallenbeck J.

Front Neurol. 2014 Jun 27;5:102. doi: 10.3389/fneur.2014.00102. eCollection 2014. Review.

39.

Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.

Oh J, Saidha S, Cortese I, Ohayon J, Bielekova B, Calabresi PA, Newsome SD.

Neurology. 2014 Mar 18;82(11):984-8. doi: 10.1212/WNL.0000000000000222. Epub 2014 Feb 14.

40.

Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases.

Han S, Lin YC, Wu T, Salgado AD, Mexhitaj I, Wuest SC, Romm E, Ohayon J, Goldbach-Mansky R, Vanderver A, Marques A, Toro C, Williamson P, Cortese I, Bielekova B.

J Immunol. 2014 Mar 15;192(6):2551-63. doi: 10.4049/jimmunol.1302884. Epub 2014 Feb 7.

41.

Evolution of tumefactive lesions in multiple sclerosis: a 12-year study with serial imaging in a single patient.

Ikonomidou VN, Richert ND, Vortmeyer A, Tovar-Moll F, Bielekova B, Cook NE, Duyn JH, Bagnato F.

Mult Scler. 2013 Oct;19(11):1539-43. doi: 10.1177/1352458513498124.

42.

Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.

Zhang Y, McClellan M, Efros L, Shi D, Bielekova B, Tang MT, Vexler V, Sheridan JP.

Mult Scler. 2014 Feb;20(2):156-64. doi: 10.1177/1352458513494488. Epub 2013 Jul 11.

43.

The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis.

Borges IT, Shea CD, Ohayon J, Jones BC, Stone RD, Ostuni J, Shiee N, McFarland H, Bielekova B, Reich DS.

Mult Scler Relat Disord. 2013 Apr 1;2(2):133-140.

44.

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA.

J Immunother. 2013 Feb;36(2):133-51. doi: 10.1097/CJI.0b013e3182829903.

45.

CNS vasculitis in a patient with MS on daclizumab monotherapy.

Ohayon J, Oh U, Richert N, Martin J, Vortmeyer A, McFarland H, Bielekova B.

Neurology. 2013 Jan 29;80(5):453-7. doi: 10.1212/WNL.0b013e31827f0f42. Epub 2013 Jan 9.

46.

Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation.

Bielekova B, Komori M, Xu Q, Reich DS, Wu T.

PLoS One. 2012;7(11):e48370. doi: 10.1371/journal.pone.0048370. Epub 2012 Nov 30.

47.

Daclizumab therapy for multiple sclerosis.

Bielekova B.

Neurotherapeutics. 2013 Jan;10(1):55-67. doi: 10.1007/s13311-012-0147-4. Review.

48.

Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis.

Perry JS, Han S, Xu Q, Herman ML, Kennedy LB, Csako G, Bielekova B.

Sci Transl Med. 2012 Aug 1;4(145):145ra106. doi: 10.1126/scitranslmed.3004140.

49.

Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS).

Jia Y, Wu T, Jelinek CA, Bielekova B, Chang L, Newsome S, Gnanapavan S, Giovannoni G, Chen D, Calabresi PA, Nath A, Cotter RJ.

Clin Proteomics. 2012 Jul 30;9(1):9. doi: 10.1186/1559-0275-9-9.

50.

Comment on "Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation".

Bielekova B, McFarland H.

Ann Neurol. 2012 Jan;71(1):148-9. doi: 10.1002/ana.22547. No abstract available.

PMID:
22275261

Supplemental Content

Loading ...
Support Center